Related Experiment Video
Updated: Jul 12, 2025
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
Alaa Alsalloum1,2, Julia Shevchenko1, Marina Fisher1
1Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.
Abstract:
TCR-like chimeric antigen receptor (CAR-T) cell therapy has emerged as a game-changing strategy in cancer immunotherapy, offering a broad spectrum of potential antigen targets, particularly in solid tumors containing intracellular antigens. In this study, we investigated the cytotoxicity and functional attributes of in vitro-generated T-lymphocytes, engineered with a TCR-like CAR receptor precisely targeting the cancer testis antigen MAGE-A4. Through viral transduction, T-cells were genetically modified to express the TCR-like CAR receptor and co-cultured with MAGE-A4-expressing tumor cells. Flow cytometry analysis revealed a significant surge in cells expressing activation markers CD69, CD107a, and FasL upon encountering tumor cells, indicating robust T-cell activation and cytotoxicity. Moreover, immune transcriptome profiling unveiled heightened expression of pivotal T-effector genes involved in immune response and cell proliferation regulation. Additionally, multiplex assays also revealed increased cytokine production and cytotoxicity driven by granzymes and soluble Fas ligand (sFasL), suggesting enhanced anti-tumor immune responses. Preliminary in vivo investigations revealed a significant deceleration in tumor growth, highlighting the therapeutic potential of these TCR-like CAR-T cells. Further investigations are warranted to validate these revelations fully and harness the complete potential of TCR-like CAR-T cells in overcoming cancer's resilient defenses.
Insights
T-cell therapy engineered to target MAGE-A4 shows promise for cancer treatment. This approach enhances T-cell activation and anti-tumor responses, leading to reduced tumor growth in preliminary studies.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- T-cell therapy, particularly chimeric antigen receptor (CAR-T) cell therapy, is a significant advancement in cancer immunotherapy.
- TCR-like CAR-T cells offer potential for targeting intracellular antigens, crucial for solid tumors.
Purpose of the Study:
- To investigate the cytotoxic and functional capabilities of T-lymphocytes engineered with a TCR-like CAR targeting MAGE-A4.
- To evaluate the anti-tumor efficacy of these engineered T-cells against MAGE-A4-expressing tumor cells.
Main Methods:
- Genetic engineering of T-lymphocytes using viral transduction to express TCR-like CAR targeting MAGE-A4.
- In vitro co-culture assays with MAGE-A4-expressing tumor cells.
- Flow cytometry for activation marker analysis (CD69, CD107a, FasL).
- Immune transcriptome profiling and multiplex assays for cytokine and granzyme analysis.
- Preliminary in vivo tumor growth studies.
Main Results:
- Engineered T-cells demonstrated significant activation and cytotoxicity upon encountering MAGE-A4-expressing tumor cells.
- Heightened expression of T-effector genes and increased production of cytotoxic molecules (granzymes, sFasL) were observed.
- Preliminary in vivo studies showed a significant deceleration in tumor growth.
Conclusions:
- TCR-like CAR-T cells targeting MAGE-A4 exhibit potent anti-tumor activity in vitro and in vivo.
- This therapy shows therapeutic potential for cancers expressing MAGE-A4.
- Further research is needed to fully validate and optimize TCR-like CAR-T cell therapy for clinical application.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
